Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and ...
March 04 2021 - 11:00AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced that it will release fourth quarter and year-end
2020 financial results after market close on Monday, March 15,
2021. Further, Catalyst management will host an
investment-community conference call at 8:30 a.m. ET on Tuesday,
March 16, 2021 to discuss the financial results and to provide a
corporate update.
Investors who wish to participate in the
conference call may do so by dialing (877) 407-8912 for domestic
and Canadian callers or (201) 689-8059 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.catalystpharma.com and clicking on the
webcast link on the Investors home page.
A webcast replay will be available on the
Catalyst website for 30 days following the call by visiting the
Investor page of the company's website
at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and other neurological and neuromuscular diseases.
Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg
tablets for the treatment of adults with LEMS was approved in 2018
by the U.S. Food & Drug Administration ("FDA"), and
Firdapse is now commercially available in the United States.
Further, Canada’s national healthcare regulatory agency, Health
Canada, recently approved the use of Firdapse (amifampridine) for
the treatment of patients in Canada with LEMS.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and has received
Orphan Drug Designation from the FDA for myasthenia
gravis.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for fiscal year 2019 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024